{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:59:42Z","timestamp":1791233982773,"version":"4.1.0"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Oligometastatic prostate cancer (OmPCa) is characterized by a restricted number of metastatic lesions confined to a limited organ range, presenting a distinct clinical challenge. The role of cytoreductive prostatectomy (CRP) in managing this specific metastatic stage has gained attention but remains controversial. This study aims to assess the effectiveness of CRP in OmPCa by synthesizing outcomes from previous studies and analyzing data from a multicenter, retrospective cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We focused on evaluating overall survival (OS), progression-free survival (PFS), cancer-specific survival (CSS), and castration-resistant prostate cancer-free survival (CRPCFS) as primary outcomes. A multicenter comparative retrospective analysis was also conducted on OmPCa patients treated with CRP versus those receiving androgen deprivation therapy (ADT) alone from January 2008 to June 2018. We gathered and analyzed data on patient demographics, tumor characteristics, surgical outcomes, and survival metrics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The quantitative analysis included 18 studies [2 randomized controlled trials (RCTs) and 16 non-RCT studies], comprising a total of 1733 patients with OmPCa, and this is the largest number of samples included in the same subject research at present. The pooled analysis demonstrated that cytoreductive surgery was associated with significantly improved OS [hazard ratio (HR) 0.50, 95% confidence interval (CI) 0.40\u20130.60], PFS (HR 0.39, 95% CI 0.27\u20130.51), CSS (HR 0.44, 95% CI 0.23\u20130.65), and CRPCFS (HR 0.48, 95% CI 0.36\u20130.59) compared to nonsurgical management. In addition, OS, PFS, and CRPCFS showed better results in the CRP group in all analyses (RCTs and non-RCTs). Additionally, in our multicenter retrospective research analysis, 64 patients with OmPCa were included, 32 underwent CRP (50%) and 32 underwent ADT alone (50%). The median follow-up time was 40.1 (18.9\u201351.3) months. The OS (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.0182), PFS (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.0297), and CRPCFS (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.0125) had statistical differences between the two matched cohorts. Moreover, we observed 8 (25%) cases of perioperative complications, with the most common being urinary incontinence (9.4%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Incorporating CRP alongside ADT in the treatment protocol for OmPCa significantly enhances patient outcomes in terms of OS, PFS, and CRPC-free survival, underscoring the potential benefit of this surgical approach in the specified patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000001968","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T11:01:58Z","timestamp":1721041318000},"page":"122-134","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Evaluating the effectiveness of cytoreductive surgery in oligometastatic prostate cancer: insights from quantitative analysis and retrospective cohort studies"],"prefix":"10.1097","volume":"111","author":[{"given":"Bisheng","family":"Cheng","sequence":"first","affiliation":[{"name":"Sun Yat-sen Memorial Hospital, Sun Yat-sen University"},{"name":"Department of Urology, Nanfang Hospital, Southern Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingheng","family":"Li","sequence":"additional","affiliation":[{"name":"Sun Yat-sen Memorial Hospital, Sun Yat-sen University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhan","family":"Fu","sequence":"additional","affiliation":[{"name":"Sun Yat-sen Memorial Hospital, Sun Yat-sen University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, Nanfang Hospital, Southern Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianlong","family":"Luo","sequence":"additional","affiliation":[{"name":"Sun Yat-sen Memorial Hospital, Sun Yat-sen University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zean","family":"Li","sequence":"additional","affiliation":[{"name":"Sun Yat-sen Memorial Hospital, Sun Yat-sen University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirong","family":"Peng","sequence":"additional","affiliation":[{"name":"Sun Yat-sen Memorial Hospital, Sun Yat-sen University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jilin","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University People\u2019s Hospital, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianghua","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Urology, Nanfang Hospital, Southern Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Huang","sequence":"additional","affiliation":[{"name":"Sun Yat-sen Memorial Hospital, Sun Yat-sen University"},{"name":"Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University"},{"name":"Guangdong Provincial Clinical Research Center for Urological Diseases, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou"},{"name":"Department of Urology, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People\u2019s Hospital, Qingyuan, Guangdong"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,1]]},"reference":[{"key":"R1-20260304","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1056\/NEJMcp2209151","article-title":"Screening for prostate cancer","volume":"388","author":"Pinsky","year":"2023","journal-title":"N Engl J Med"},{"key":"R2-20260304","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1097\/JS9.0000000000000685","article-title":"Different therapeutic regimens in the treatment of metastatic prostate cancer","volume":"109","author":"Huang","year":"2023","journal-title":"Int J Surg"},{"key":"R3-20260304","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41698-024-00503-2","article-title":"A protein-encoding CCDC7 circular RNA inhibits the progression of prostate cancer by up-regulating FLRT3","volume":"8","author":"Wang","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"R4-20260304","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.eururo.2023.06.013","article-title":"Primary whole-gland ablation for the treatment of clinically localized prostate cancer: a focal therapy society best practice statement","volume":"84","author":"Deivasigamani","year":"2023","journal-title":"Eur Urol"},{"key":"R5-20260304","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1097\/JS9.0000000000001308","article-title":"Assessment of treatment outcomes: cytoreductive surgery compared to radiotherapy in oligometastatic prostate cancer - an in-depth quantitative evaluation and retrospective cohort analysis","volume":"110","author":"Cheng","year":"2024","journal-title":"Int J Surg"},{"key":"R6-20260304","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.22.00644","article-title":"Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials","volume":"40","author":"Deek","year":"2022","journal-title":"J Clin Oncol"},{"key":"R7-20260304","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","article-title":"Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND phase 2 randomized clinical trial","volume":"9","author":"Tang","year":"2023","journal-title":"JAMA Oncol"},{"key":"R8-20260304","doi-asserted-by":"crossref","first-page":"e2235345","DOI":"10.1001\/jamanetworkopen.2022.35345","article-title":"Survival outcomes after radiotherapy for the treatment of synchronous oligometastatic prostate cancer","volume":"5","author":"Huynh","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R9-20260304","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1097\/JS9.0000000000000339","article-title":"Role of local ablative treatment in oligometastatic non-small cell lung cancer: a meta-analysis","volume":"109","author":"Rim","year":"2023","journal-title":"Int J Surg"},{"key":"R10-20260304","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41571-022-00675-5","article-title":"Advances in the management of peritoneal malignancies","volume":"19","author":"Kepenekian","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"R11-20260304","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2017.03.020","article-title":"Local therapy improves survival in metastatic prostate cancer","volume":"72","author":"Leyh-Bannurah","year":"2017","journal-title":"Eur Urol"},{"key":"R12-20260304","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.eururo.2018.07.006","article-title":"Comparison of perioperative outcomes between cytoreductive radical prostatectomy and radical prostatectomy for nonmetastatic prostate cancer","volume":"74","author":"Preisser","year":"2018","journal-title":"Eur Urol"},{"key":"R13-20260304","doi-asserted-by":"crossref","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"key":"R14-20260304","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"R15-20260304","doi-asserted-by":"crossref","first-page":"106165","DOI":"10.1016\/j.ijsu.2021.106165","article-title":"STROCSS 2021: Strengthening the reporting of cohort, cross-sectional and case\u2013control studies in surgery","volume":"96","author":"Mathew","year":"2021","journal-title":"Int J Surg"},{"key":"R16-20260304","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"R17-20260304","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1097\/JS9.0000000000000441","article-title":"The gap before real clinical application of imaging-based machine-learning and radiomic models for chemoradiation outcome prediction in esophageal cancer: a systematic review and meta-analysis","volume":"109","author":"Yang","year":"2023","journal-title":"Int J Surg"},{"key":"R18-20260304","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R19-20260304","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S2213-8587(23)00122-5","article-title":"Enteroviruses and risk of islet autoimmunity or type 1 diabetes: systematic review and meta-analysis of controlled observational studies detecting viral nucleic acids and proteins","volume":"11","author":"Isaacs","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R20-20260304","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12957-021-02265-8","article-title":"The efficacy of cytoreductive surgery for oligometastatic prostate cancer: a meta-analysis","volume":"19","author":"Cheng","year":"2021","journal-title":"World J Surg Oncol"},{"key":"R21-20260304","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/JS9.0000000000000284","article-title":"The correlation of intraoperative oliguria with acute kidney injury after noncardiac surgery: a systematic review and meta-analysis","volume":"109","author":"Pang","year":"2023","journal-title":"Int J Surg"},{"key":"R22-20260304","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1046\/j.1464-410X.1997.33215.x","article-title":"Early endocrine therapy versus radical prostatectomy combined with early endocrine therapy for stage D1 prostate cancer","volume":"79","author":"Schmeller","year":"1997","journal-title":"Br J Urol"},{"key":"R23-20260304","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0022-5347(01)61640-9","article-title":"Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison","volume":"161","author":"Ghavamian","year":"1999","journal-title":"J Urol"},{"key":"R24-20260304","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S0302-2838(02)00134-3","article-title":"Clinical outcome of patients with lymph node positive prostate cancer after radical prostatectomy versus androgen deprivation","volume":"41","author":"Grimm","year":"2002","journal-title":"Eur Urol"},{"key":"R25-20260304","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.eururo.2009.12.034","article-title":"Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer","volume":"57","author":"Engel","year":"2010","journal-title":"Eur Urol"},{"key":"R26-20260304","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/j.1464-410X.2010.09730.x","article-title":"Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study","volume":"107","author":"Steuber","year":"2011","journal-title":"BJU Int"},{"key":"R27-20260304","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.juro.2014.09.089","article-title":"Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case\u2013control study","volume":"193","author":"Heidenreich","year":"2015","journal-title":"J Urol"},{"key":"R28-20260304","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/pcan.2016.63","article-title":"Treatment of M1a\/M1b prostate cancer with or without radical prostatectomy at diagnosis","volume":"20","author":"Moschini","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R29-20260304","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.kjms.2017.07.002","article-title":"Cytoreductive cryosurgery in patients with bone metastatic prostate cancer: a retrospective analysis","volume":"33","author":"Sheng","year":"2017","journal-title":"Kaohsiung J Med Sci"},{"key":"R30-20260304","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.euf.2017.06.016","article-title":"Does cytoreductive prostatectomy really have an impact on prognosis in prostate cancer patients with low-volume bone metastasis? Results from a prospective case\u2013control study","volume":"3","author":"Steuber","year":"2017","journal-title":"Eur Urol Focus"},{"key":"R31-20260304","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.juro.2017.01.063","article-title":"Impact of radical prostatectomy on long-term oncologic outcomes in a matched cohort of men with pathological node positive prostate cancer managed by castration","volume":"198","author":"Bhindi","year":"2017","journal-title":"J Urol"},{"key":"R32-20260304","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/bju.13992","article-title":"Does robot-assisted radical prostatectomy benefit patients with prostate cancer and bone oligometastases?","volume":"121","author":"Jang","year":"2018","journal-title":"BJU Int"},{"key":"R33-20260304","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.urology.2019.03.040","article-title":"Oncological outcome of cytoreductive radical prostatectomy in prostate cancer patients with bone oligometastases","volume":"131","author":"Lan","year":"2019","journal-title":"Urology"},{"key":"R34-20260304","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.euros.2021.05.006","article-title":"The role of cytoreductive radical prostatectomy in the treatment of newly diagnosed low-volume metastatic prostate cancer. results from the local treatment of metastatic prostate cancer (LoMP) registry","volume":"29","author":"Lumen","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"R35-20260304","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/pros.24170","article-title":"Does surgery benefit patients with oligometastatic or metastatic prostate cancer? - A retrospective cohort study and meta-analysis","volume":"81","author":"Si","year":"2021","journal-title":"Prostate"},{"key":"R36-20260304","first-page":"934","article-title":"\"Efficacy of robot-assisted radical prostatectomy for oligometastatic prostate cancer\"","volume":"26","author":"Zhi","year":"2021","journal-title":"Journal of Modern Urology"},{"key":"R37-20260304","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.euo.2022.06.001","article-title":"Combination of androgen deprivation therapy with radical local therapy versus androgen deprivation therapy alone for newly diagnosed oligometastatic prostate cancer: a phase II randomized controlled trial","volume":"5","author":"Dai","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"R38-20260304","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.3390\/cancers14092313","article-title":"Oligometastatic prostate cancer: a comparison between multimodality treatment vs. androgen deprivation therapy alone","volume":"14","author":"Mistretta","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R39-20260304","first-page":"460","article-title":"\"Efficacy and prognosis of cytoreductive radical prostatectomy combined with androgen deprivation therapy for oligometastatic prostate cancer\"","volume":"39","author":"Qi","year":"2023","journal-title":"The Journal of Practical Medicine"},{"key":"R40-20260304","first-page":"934","article-title":"Efficacy of robot-assisted radical prostatectomy for oligometastatic prostate cancer","volume":"26","author":"Zhi","year":"2021","journal-title":"J Modern Urol"},{"key":"R41-20260304","first-page":"460","article-title":"Efficacy and prognosis of cytoreductive radical prostatectomy combined with androgen deprivation therapy for oligometastatic prostate cancer","volume":"39","author":"Qi","year":"2023","journal-title":"J Pract Med"},{"key":"R42-20260304","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/S1470-2045(22)00752-5","article-title":"Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium","volume":"24","author":"Kroeze","year":"2023","journal-title":"Lancet Oncol"},{"key":"R43-20260304","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.eururo.2023.06.008","article-title":"Prostate-specific Membrane Antigen Reporting and Data System Version 2.0","volume":"84","author":"Werner","year":"2023","journal-title":"Eur Urol"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000001968","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T12:06:39Z","timestamp":1772625999000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000001968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000001968","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,15]]},"assertion":[{"value":"2024-05-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}